A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy

Timothy Rajakumar, Rastislav Horos, Julia Jehn, Judith Schenz, Thomas Muley, Oana Pelea, Sarah Hofmann, Paul Kittner, Mustafa Kahraman, Marco Heuvelman, Tobias Sikosek, Jennifer Feufel, Jasmin Skottke, Dennis Nötzel, Franziska Hinkfoth, Kaja Tikk, Alberto Daniel-Moreno, Jessika Ceiler, Nathaniel Mercaldo, Florian Uhle, Sandra Uhle, Markus A Weigand, Mariam Elshiaty, Fabienne Lusky, Hannah Schindler, Quentin Ferry, Tatjana Sauka-Spengler, Qianxin Wu, Klaus F Rabe, Martin Reck, Michael Thomas, Petros Christopoulos, Bruno R Steinkraus
doi: https://doi.org/10.1101/2021.10.31.21265722

Article Information

doi 
https://doi.org/10.1101/2021.10.31.21265722
History 
  • February 1, 2022.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Timothy Rajakumar1,
  2. Rastislav Horos1,
  3. Julia Jehn1,
  4. Judith Schenz2,
  5. Thomas Muley3,
  6. Oana Pelea4,
  7. Sarah Hofmann1,
  8. Paul Kittner1,
  9. Mustafa Kahraman1,
  10. Marco Heuvelman1,
  11. Tobias Sikosek1,
  12. Jennifer Feufel1,
  13. Jasmin Skottke1,
  14. Dennis Nötzel1,
  15. Franziska Hinkfoth1,
  16. Kaja Tikk1,
  17. Alberto Daniel-Moreno1,
  18. Jessika Ceiler1,
  19. Nathaniel Mercaldo5,
  20. Florian Uhle2,
  21. Sandra Uhle2,
  22. Markus A Weigand2,
  23. Mariam Elshiaty3,
  24. Fabienne Lusky3,
  25. Hannah Schindler3,
  26. Quentin Ferry6,
  27. Tatjana Sauka-Spengler4,
  28. Qianxin Wu7,
  29. Klaus F Rabe8,9,
  30. Martin Reck8,
  31. Michael Thomas3,
  32. Petros Christopoulos3 and
  33. Bruno R Steinkraus1,*
  1. 1Hummingbird Diagnostics GmbH, Im Neuenheimer Feld 583, 69120 Heidelberg, Germany
  2. 2Department of Anesthesiology, Heidelberg University Hospital, Heidelberg, Germany
  3. 3Thoraxklinik and National Center for Tumor Diseases (NCT) at Heidelberg University Hospital, Germany
  4. 4MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
  5. 5Institute for Technology Assessment, Department of Radiology, Massachusetts General Hospital, Boston, United States
  6. 6Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, United States
  7. 7Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, United Kingdom
  8. 8LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany
  9. 9Department of Medicine, Christian Albrechts University of Kiel, Kiel, Germany
  1. ↵*correspondence should be addressed to Bruno R Steinkraus, PhD, bsteinkraus{at}hb-dx.com
Back to top
Posted February 01, 2022.
Download PDF
Data/Code
Email
A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy
Timothy Rajakumar, Rastislav Horos, Julia Jehn, Judith Schenz, Thomas Muley, Oana Pelea, Sarah Hofmann, Paul Kittner, Mustafa Kahraman, Marco Heuvelman, Tobias Sikosek, Jennifer Feufel, Jasmin Skottke, Dennis Nötzel, Franziska Hinkfoth, Kaja Tikk, Alberto Daniel-Moreno, Jessika Ceiler, Nathaniel Mercaldo, Florian Uhle, Sandra Uhle, Markus A Weigand, Mariam Elshiaty, Fabienne Lusky, Hannah Schindler, Quentin Ferry, Tatjana Sauka-Spengler, Qianxin Wu, Klaus F Rabe, Martin Reck, Michael Thomas, Petros Christopoulos, Bruno R Steinkraus
medRxiv 2021.10.31.21265722; doi: https://doi.org/10.1101/2021.10.31.21265722
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area